Signal2026-06-22
ClinicalTrials.gov

[PHASE2] A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

Part of

Molecular Profiling In Endocrine Neoplasms

Open primary sourceSee the whole picture